sm

Husband, part time engineer, full time ALS patient. Still hopeful about the future.

[sm @svrg72]

Made this sheet to track all things ALS https://t.co/y6JfbTMrVz

[sm @svrg72]

@mndsmart It was a poor choice to begin with..

[sm @svrg72]

@PharmAust will there be extended Access?

[sm @svrg72]

https://t.co/RejXlEqqok #fasudil #ALS

[sm @svrg72]

https://t.co/5TefSgGkbb

[sm @svrg72]

@BrielmaierL @Asha_TXs is developing ASHA-091, a highly specific inhibitor of #DRP1 activation, for #ALS, https://t.co/fM8tyFyYfg

[sm @svrg72]

@AndreaBackman05 Being a patient of ALS, I would gladly do this if I had an opportunity to do it safely..

[sm @svrg72]

@AndreaBackman05 There is also an ongoing trial in Italy trying to obtain some conclusive answers on this topic, see this article https://t.co/Xv3yXibEEw

[sm @svrg72]

#ALS #FMT

[sm @svrg72]

https://t.co/sCFezwDsJr

[sm @svrg72]

@VPResearch_ALS I wonder what is going to happen with the #ATXN2 programs from @AviadoBio, Affinia Therapeutics $AFTX, @ProMISinc, @MazeInBiotech.. Should they scrap them or push to the clinic and hope for the best? #ALS

[sm @svrg72]

@VPResearch_ALS What can be learned from this result? Can anything be generalized? Or is it just thanks and let's try another one?

[sm @svrg72]

@AnavexLifeSci How do your compounds compare to #Pridopidine? Is there a reason to believe that they could do better for diseases like ALS? The mechanism of action seems to be the same

[EUpALS @EUpALS]

Top line results of the TUDCA-ALS trial are announced at https://t.co/cAWUyKHqOH.
The study did not meet the primary endpoint and there were also no significant differences observed across secondary endpoints at 18 months. Full results will likely be presented at ENCALS 2024.

[Allison DeAngelis @ADeAngelis_bio]

Amylyx Pharmaceuticals' treatment for ALS has failed a large clinical trial — a stunning outcome that now has the company considering a voluntary withdrawal of the approved medicine from the market.

https://t.co/qumRNqnaAO @adamfeuerstein

[sm @svrg72]

@adamfeuerstein It started in 2019, so no rush

[Rothstein Lab @Rothstein_Lab]

Restoring functional TDP-43 oligomers in ALS and laminopathic cellular models through baicalein-induced reconfiguration of TDP-43 aggregates https://t.co/DDaprc5ITa

[sm @svrg72]

@suvankarpal @mndsmart So what's the current success rate?

[sm @svrg72]

@wolfnstuff @9NewsMelb @reid_butler9 https://t.co/k6GAjDkrrw

[sm @svrg72]

@EUpALS @ferrerforgood So does this mean that #Edaravone needs to be expensive to work? What does this mean for #Radicava?